JNNP:脑卒中后能否独立行走,取决于那些因素?

2021-04-16 Freeman MedSci原创

诸多因素影响,脑卒中后能否独立行走

急性脑卒中后约有三分之二的人会存在独立行走的困难,大部分幸存者在脑卒中后3个月仍有这种困难。中风幸存者认为中风后的行走是一个高度优先的研究领域。与距离、外观或速度相比,幸存者最感兴趣的是步行独立性的恢复(即不需要他人的双手帮助)。从医疗服务的角度来看,独立行走对于康复目标和出院目的地的决策非常重要。因此,延迟独立行走会给脑卒中幸存者、其家庭和医疗系统带来巨大负担。

了解与独立行走恢复相关的因素,对建立康复目标和制定出院计划非常重要。步行能力的直接测量(例如,10 米步行测试)与改良的Rankin 量表(mRS)相比,更能反映步行能力,后者不能统一测量步行能力,但过去一直用于此目的。

卒中前和急性卒中因素似乎都与独立行走有关。年纪较轻通常与行走能力的恢复呈正相关,而性别似乎没有关联。卒中严重程度、卒中类型和卒中前合并症(如糖尿病)与步行恢复的关系尚无定论。

然而,这些因素与直接步行结果之间的关联证据有限。对于卒中前存在的医疗合并症与卒中后无辅助行走的关联,几乎没有证据。迄今为止,神经影像学因素(如卒中类型、卒中大脑半球、病变体积)与独立行走的关联尚未得到广泛研究。

藉此,澳大利亚墨尔本大学的Caitlin Kennedy等人,通过利用A Very Early Rehabilitation Trial (AVERT)的数据调查了卒中前因素和卒中后急性收集的因素与无扶助行走50 m天数之间的关系。

临床结局是50米独立行走的恢复情况,测试时间为卒中后24小时至3个月。


先验定义(priori)的因素包括,参与者人口统计学:年龄、性别、手部;卒中前:高血压、缺血性心脏病、高胆固醇血症、糖尿病、心房颤动;卒中相关:卒中严重程度、卒中类型、缺血性卒中位置、卒中半球、溶栓,通过使用特定原因竞争风险Cox比例危险模型调查了与独立行走的关联。

统计结果的效应度为对年龄、卒中严重程度和AVERT干预进行调整后的病因HR(cause-specific adjusted HR,caHR)。

结他们共纳入2100名卒中参与者(中位年龄73岁,NIHSS量表7级,<1%缺失数据)。无人搀扶行走50米的中位时间为6天(IQR 2-63),75%的人在3个月前实现独立行走。

调整后的Cox回归表明,恢复独立行走的速度较慢与年龄较大(caHR 0.651,95% CI 0.569~0.746)、糖尿病(caHR 0.836,95% CI 0.740~0. 945)、严重卒中(caHR 0.094,95% CI 0.072~0.122)、出血性卒中(caHR 0.790,95% CI 0.675~0.925)和右半球卒中(caHR 0.796,95% CI 0.714~0.887)。

这个研究的重要意义在于,发现了与独立行走恢复相关的重要因素,并强调了针对亚群,特别是出血性和重度卒中患者,量身定制运动康复训练方案的必要性。


原文出处:

Kennedy, C., Bernhardt, J., Churilov, L., Collier, J. M., Ellery, F., Rethnam, V., ... & Hayward, K. S. (2021). Factors associated with time to independent walking recovery post-stroke. _Journal of Neurology, Neurosurgery & Psychiatry_.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 七安

    三人行,必有我师。 #梅斯医学科研互助群# 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 妮妮阿

    🙌

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 妮妮阿

    👍

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 妮妮阿

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 妮妮阿
  7. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 二爽

    学习了学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1671425, encodeId=3af016e142591, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Mon Oct 25 04:18:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957504, encodeId=74d795e5042c, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 09:44:52 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957534, encodeId=5f1395e5344b, content=🙌, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:31:08 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957533, encodeId=089195e5333a, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:20 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957532, encodeId=9ca795e532ff, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:09 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957531, encodeId=d8c495e531fc, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210416/788a7f7e6afd44c2bbf80789f86648e5/d8e271f93c0842cca096818ad4390ccb.jpg, createdBy=69a95480157, createdName=妮妮阿, createdTime=Fri Apr 16 10:29:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957488, encodeId=431995e4887d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/9e5998de75824d5f8a8e76ad7ca79433/206fffa392c54ae5a60152c166e2f362.jpg, createdBy=ab0d5455599, createdName=二爽, createdTime=Fri Apr 16 08:54:49 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026818, encodeId=aaf51026818b4, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Apr 16 08:18:53 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Stroke:中性粒细胞与淋巴细胞比值可预测脑卒中患者再灌注治疗后早期脑水肿和临床恶化

全身炎症与卒中再灌注治疗后早期CED的严重程度有关。容易获得的炎症标志物有可能为严重神经系统并发症并影响长期功能结局的患者传递了早期预警信息。

Stroke:脑卒中病变部位与抑郁症状之间的相关性分析

左腹外侧前额叶皮层病变增加了卒中后抑郁症状的风险。大脑右侧半球内的病变与抑郁症状无关。认识到左额叶病变是危险因素,应通过更好的危险分层来帮助早期诊断卒中后抑郁。

Neurology: 加拿大20万人研究:过去15年,脑卒中的发病率和病死率均大幅下降

加拿大20万人研究-过去15年,脑卒中的发病率和病死率均大幅下降

JACC:糖尿病前期也可增加非瓣膜性房颤患者的卒中风险

糖尿病(DM)可增加非瓣膜性心房颤动(NVAF)的栓塞风险,糖尿病前期是否也会增加这类患者的栓塞风险?

Stroke: 脑容量越大,脑中风预后越好!

脑容量越大,脑中风预后越好!